Assessment of comorbid pathology in patients with breast cancer

DOI: https://doi.org/10.29296/25877305-2023-11-15
Issue: 
11
Year: 
2023

D. Orlova; Professor V. Stolyarova, MD; Yu. Skopina, Candidate of Medical Sciences; S. Shokina, Candidate of Medical Sciences; E. Davydova
National Research Ogarev Mordovia State University, Saransk

The incidence of cardiovascular diseases associated with the treatment of malignancies varies widely depending on the antitumor therapy, its duration, and concomitant diseases of a patient. Objective. To assess comorbid pathology in patients with breast cancer (BC). Material and methods. The study included 100 women with breast cancer aged 30 to 80 years. The patients were divided into 5 groups according to their age. The following were assessed: primary and concomitant diseases, history of the primary disease, results of instrumental methods of investigation – ECG, chemotherapy, radiotherapy, and metabolic therapy. The Charlson comorbidity index was calculated, and the one-year death risk and 10-year survival rate in patients with BC were assessed. Results. The following comorbid pathologies were the most common in the study group patients: hypertension, angina pectoris, chronic gastritis, and myocardiodystrophy. Increasing prevalence of comorbid pathology, significant growth of Charlson comorbidity index score, and deterioration of prognostic indexes were revealed in patients older than 40. Conclusion. In patients with BC aged 40 and older, cardiovascular pathology, particularly hypertension, angina pectoris, myocardiodystrophy, prevails in the comorbidity structure. Patients most often had a combination of cancer with two or more comorbidities. A significant increase in the Charlson comorbidity index score was observed with age in all patients with BC. According to the prognostic value of the Charlson comorbidity index, 56% of the studied patients with BC have a high risk of one-year mortality and a low 10-year survival rate.

Keywords: 
cardiovascular diseases
oncological diseases
breast cancer
cardiotoxicity
comorbidity
Charlson comorbidity index.



References: 
  1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2022; 239 с. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2017 godu. M.: MNIOI im. P.A. Gertsena – filial FGBU «NMIRTs» Minzdrava Rossii, 2022; 239 р. (in Russ.)].
  2. Аксель Е.М. Злокачественные новообразования молочной железы: состояние онкологической помощи, заболеваемость и смертность. Маммология. 2006; 1: 9–13 [Aksel E.M. Breast malignancies: the state-of-the-art of oncological care, morbidity, and mortality. Mammologiya. 2006; 1: 9–13 (in Russ.)].
  3. Miller K.D., Siegel R.L., Lin C.C. et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2016; 66 (4): 271–9. DOI: 10.4236/oju.2013.33031
  4. Reulen R.C., Winter D.L., Frobisher C. et al. British Childhood Cancer Survivor Study Steering Group. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010; 304 (2): 172–9. DOI: 10.1001/jama.2010.923
  5. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2014; 64 (4): 252–71. DOI: 10.3322/caac.21235
  6. Siegel R., DeSantis C., Virgo K. et al. Cancer treatment and survivorship statistics. CA: Cancer J Clin. 2012; 62 (4): 220–41. DOI: 10.3322/caac.21149
  7. DeSantis C., Ma J., Bryan L. et al. Breast cancer statistics. CA: Cancer J Clin. 2014; 64 (1): 52–62. DOI: 10.3322/caac.21203
  8. Curigliano G., Cardinale D., Suter T. et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy. ESMO Clinical Practice Guidelines. Ann Oncol. 2012; 23 (7): 155–66. DOI: 10.1093/annonc/mds293
  9. Curigliano G., Cardinale D., Dent S. et al. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA: Cancer J Clin. 2016; 66 (4): 309–25. DOI: 10.3322/caac.21341
  10. Colby S.L., Ortman J.M. Projections of the size and composition of the US population: 2014 to 2060: Population estimates and projections. US Sensus Bureau. Washington, DC: US Department of Commerce, Economics and Statistics Administration, 2017; рр. 25–1143.
  11. Cubbon R.M., Lyon A.R. Cardio-oncology: Concepts and practice. Indian Heart J. 2016; 68 (1): 77–85. DOI: 10.1016/j.ihj.2016.01.022
  12. Benjamin E.J., Blaha M.J., Chiuve S.E. et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics – 2017 Update: A Report From the American Heart Association. Circulation. 2017; 135 (10): 146–603. DOI: 10.1161/CIR.0000000000000485
  13. Gernaat S.M., Ho P.J., Rijnberg N. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017; 164 (3): 537–55. DOI: 10.1007/s10549–017–4282–9
  14. Bradshaw P.T., Stevens J., Khankari N. et al. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology (Cambridge, Mass). 2016; 27 (1): 6–13. DOI: 10.1097/EDE.0000000000000394
  15. Fowler H., Belot A., Ellis L. et al. Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers. BMC Cancer. 2020; 20 (1): 2. DOI: 10.1186/s12885-019-6472-9